Amarin Corp Plc (AMRN)

[ziploc_1]

Capt....Quote from articled you linked your post 406444 "Inflammation and hyperlipidaemia jointly contribute to atherothrombotic disease. However, when people are treated with intensive statin therapy, the relative contributions of inflammation and hyperlipidaemia to the risk of future cardiovascular events might change, which has implications for the choice of adjunctive cardiovascular risk"


The linked article goes on to illustrate that hsCRP is reduced by 40% using Vascepa vs. placebo!

It's the lipid lowering effect of statin TOGETHER with the anti-inflammatory effect of Vascepa that are responsible for the remarkable reduction of CVD.

Sarissa needs to make this fact known...Right now, patients and Docs think the statin does the whole job.

A FDC might help illustrate the necessity of adding Vascepa to a statin to achieve the desired results.